Literature for AZD3839 (A01.004 inhibitor)

(Topics flags: A Assay, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2018
1. Mondragon-Rodriguez,S., Gu,N., Manseau,F. and Williams,S.
   Alzheimer's transgenic model is characterized by very early brain network alterations and beta-CTF fragment accumulation: reversal by beta-secretase inhibition
   Front Cell Neurosci12, 121-121. PubMed  Europe PubMed DOI  I
2017
2. Liu,R., Liu,Y.C., Meng,J., Zhu,H. and Zhang,X.
   A microfluidics-based mobility shift assay to identify new inhibitors of beta-secretase for Alzheimer's disease
   Anal Bioanal Chem409, 6635-6642. PubMed  Europe PubMed DOI  A  I
2013
3. Lindgren,A., Eklund,G., Turek,D., Malmquist,J., Swahn,B.M., Holenz,J., von Berg,S., Karlstrom,S. and Bueters,T.
   Biotransformation of two beta-secretase inhibitors including ring opening and contraction of a pyrimidine ring
   Drug Metab Dispos41, 1134-1147. PubMed  Europe PubMed DOI  I
2012
4. Swahn,B.M., Kolmodin,K., Karlstrom,S., von Berg,S., Soderman,P., Holenz,J., Berg,S., Lindstrom,J., Sundstrom,M., Turek,D., Kihlstrom,J., Slivo,C., Andersson,L., Pyring,D., Rotticci,D., Ohberg,L., Kers,A., Bogar,K., von Kieseritzky,F., Bergh,M., Olsson,L.L., Janson,J., Eketjall,S., Georgievska,B., Jeppsson,F. and Falting,J.
   Design and synthesis of beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of beta-amyloid peptides
   J Med Chem55, 9346-9361. PubMed  Europe PubMed DOI  I